SLC5A2 and hydrops fetalis: Individually, therapy lowered all-cause mortality (HR: 0.72; 95% CI: 0.53, 0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p < 0.01).<h4>Conclusion</h4>In patients with severe AS undergoing TAVR, SGLT2 inhibitors were associated with significant reductions in all-cause mortality and HF hospitalisations.